Sense raises ?
Sense A/S out of Taastrup, Denmark is developing a continuous blood pressure monitor that doesn???t rely on a typical pressure cuff, but rather on a patch that has electrodes that sense the changing impedance of tissue around a vessel and convert it into a BP reading. Measuring other characteristics in electrical signal can also identify vascular stiffness and pulse velocity.
The company just raised ??? 4.5 million in a third investment round and believes that a 510(k) approval from the FDA is likely sufficient to get the device to market.
The Danish company Sense A/S develops ContiPress???, which continuously measures the patient???s blood pressure 24 hours a day, down to every 10 second day and night, without the user noticing. ContiPress??? consists of an intelligent patch, which the doctor or nurse places on the patient???s upper arm. From there, the unit monitors the patient???s blood pressure over 24 hours and stores the data for subsequent analysis via an enclosed piece of software. The result is comprehensive data about the patient???s blood pressure over 24 hours and thus an optimal basis for making the correct diagnosis.
The Danish company Sense A/S just raised ??? 4.5 million for their groundbreaking medical technology for blood pressure measurement. The technology works seamlessly and will remedy incorrect diagnostics of hypertension at the physicians’ offices, which themselves can cause elevated readings. The total investment from venture fund SEED Capital and V??kstfonden will be used to refine the product and for commercial launch in 2013.
High blood pressure affects more than ?? of the Western world population and it is estimated that up to 12% of all deaths can be linked to this disorder. Hypertension is therefore one of the world’s largest disease areas and the most important factor in the treatment of this is an accurate diagnosis. Current diagnostic solution of choice is the measurement of blood pressure at the physicians’ offices, and typically using the cuff method. However this solution has a number of challenges including discomfort with the measurement itself and nervousness during the consultation which both may contribute to erroneous measurements. In addition, the realization is that a variety of cardiovascular diseases can be diagnosed much better by measuring blood pressure over a standard 24-hour circadian rhythm, and for this the cuff method is not very suitable.
The Danish company Sense A/S develops ContiPress???, which continuously measures the patient’s blood pressure 24 hours a day, down to every 10 second day and night, without the user noticing.
ContiPress??? consists of an intelligent patch, which the doctor or nurse places on the patient’s upper arm. From there, the unit monitors the patient’s blood pressure over 24 hours and stores the data for subsequent analysis via an enclosed piece of software. The result is comprehensive data about the patient’s blood pressure over 24 hours and thus an optimal basis for making the correct diagnosis.
Accurate blood pressure readings are essential requirements for the diagnosis, management, and treatment of hypertension.
It is also being realized that measurement of BP variations of a 24-hour period is important: it gives a much better indication of the state of the patient/person than measurements taken at single discrete points in time.
Vascular compliance (VC) is defined as the volume change devided by the pressure change. It is a good measure of the state of the vascular system especially when measured in the major arteries or veins.
Vascular stiffness is in our technology necessary in order to measure calibrated values of BP, but measuring vascular stiffness and BP it is simple also to provide vascular compliance.
The overall principle is based on joint measurements of vascular distention and vascular stiffness. From these two quantities it is possible to calculate the BP and the vascular compliance.
Sense has raised ??? 4.5 million in an investment round with venture fund SEED Capital and V??kstfonden. It is the company third round, since it was founded in 2006 in connection with an investment from SEED Capital. Second round of investment came from SEED Capital and V??kstfonden in 2010. ContiPress??? is currently a prototype that has been clinically tested on people with very large differences in both blood pressure, BMI (body mass index) and age with promising results that verify the measurement principle. The investment round will be used to refine the device and try ContiPress??? in a more extensive clinical testing within the expected commercial launch.
SEED Capital Denmark